Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors

David Harrison(Chelmsford and Essex Hospital), Alan P. Watt(Essex Cardiothoracic Centre), Jane Scanlon(Chelmsford and Essex Hospital), Iain Simpson(Charles River Laboratories (United Kingdom)), Grant Wishart(Charles River Laboratories (United Kingdom)), Christopher A. Gabel(Community Health Systems - Lutheran Hospital), John R. Doedens(Univera (United States)), Pamela J. Smolak(Benjamin Franklin Institute of Technology), Arwel Lewis(Charles River Laboratories (United Kingdom)), M. Katharine Holloway, Mark G. Bock, Andrew Sharpe(Saskatchewan Research Council (Canada))
ACS Medicinal Chemistry Letters
August 1, 2022
Cited by 23


Related Papers